hNUDC promotes the cell proliferation and differentiation in a leukemic cell line via activation of the thrombopoietin receptor (Mpl).

abstract：:We previously identified autoantibodies to the endocytic-associated protein Huntingtin-interacting protein 1-related (HIP1R) in diffuse large B-cell lymphoma (DLBCL) patients. HIP1R regulates internalization of cell surface receptors via endocytosis, a process relevant to many therapeutic strategies including CD20 tar...

journal_title：Leukemia

authors： Wong KK,Gascoyne DM,Brown PJ,Soilleux EJ,Snell C,Chen H,Lyne L,Lawrie CH,Gascoyne RD,Pedersen LM,Møller MB,Pulford K,Murphy D,Green TM,Banham AH

更新日期：2014-02-01 00:00:00

abstract：:The B-cell receptor (BCR) and its immature form, the precursor-BCR (pre-BCR), have a central role in the control of B-cell development, which is dependent on a sequence of cell-fate decisions at specific antigen-independent checkpoints. Pre-BCR expression provides the first checkpoint, which controls differentiation o...

journal_title：Leukemia

authors： Eswaran J,Sinclair P,Heidenreich O,Irving J,Russell LJ,Hall A,Calado DP,Harrison CJ,Vormoor J

更新日期：2015-08-01 00:00:00

abstract：:The Brazilian Cooperative Group for Treatment of Childhood Acute Lymphocytic Leukemia (GBTLI) has started clinical activities trials in 1980. Three consecutive multicenter studies in children with unprevious treated ALL have been completed including 994 patients. The first GBTLI-80 accrued 203 children from 1980 to 19...

journal_title：Leukemia

authors： Brandalise S,Odone V,Pereira W,Andrea M,Zanichelli M,Aranega V

更新日期：1993-08-01 00:00:00

abstract：:Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against chronic lymphocytic leukemia (CLL) in early clinical trials. Understanding the molecular ...

journal_title：Leukemia

authors： Cheng S,Ma J,Guo A,Lu P,Leonard JP,Coleman M,Liu M,Buggy JJ,Furman RR,Wang YL

更新日期：2014-03-01 00:00:00

abstract：:CD44 variant isoforms (CD44v) have been shown to be important factors in adverse prognosis in hematological malignancies. To investigate whether CD44 expression is associated with malignant transformation in multiple myeloma, RNA and protein expression of CD44 standard (CD44s) and CD44v4, v6, v9, v10 containing isofor...

journal_title：Leukemia

authors： van Driel M,Günthert U,Stauder R,Joling P,Lokhorst HM,Bloem AC

更新日期：1998-11-01 00:00:00

abstract：:The combination of the anti-viral agents, zidovudine (AZT) and interferon-alpha (IFN), is a potent treatment of HTLV-I-associated adult T cell leukemia/lymphoma (ATL). In this study we investigate the possible mechanism of action of this combination by examining several cellular parameters including cell proliferation...

journal_title：Leukemia

authors： Bazarbachi A,Nasr R,El-Sabban ME,Mahé A,Mahieux R,Gessain A,Darwiche N,Dbaibo G,Kersual J,Zermati Y,Dianoux L,Chelbi-Alix MK,de Thé H,Hermine O

更新日期：2000-04-01 00:00:00

abstract：:PCR-based monitoring of minimal residual disease (MRD) in acute leukemias can be achieved via detection of fusion gene transcripts of chromosome aberrations or detection of immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements. We wished to assess whether both PCR targets are complementary in acute myeloid...

journal_title：Leukemia

authors： Boeckx N,Willemse MJ,Szczepanski T,van der Velden VH,Langerak AW,Vandekerckhove P,van Dongen JJ

更新日期：2002-03-01 00:00:00

abstract：:Clinical outcomes for multiple myeloma (MM) are highly heterogeneous and it is now clear that pivotal genetic events are the primary harbingers of such variation. These findings have broad implications for counseling, choice of therapy and the design and interpretation of clinical investigation. Indeed, as in acute le...

journal_title：Leukemia

authors： Stewart AK,Bergsagel PL,Greipp PR,Dispenzieri A,Gertz MA,Hayman SR,Kumar S,Lacy MQ,Lust JA,Russell SJ,Witzig TE,Zeldenrust SR,Dingli D,Reeder CB,Roy V,Kyle RA,Rajkumar SV,Fonseca R

更新日期：2007-03-01 00:00:00

abstract：:Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemi...

journal_title：Leukemia

authors： Fabarius A,Giehl M,Frank O,Duesberg P,Hochhaus A,Hehlmann R,Seifarth W

更新日期：2005-09-01 00:00:00

abstract：:In this study, fluorescence in situ hybridization (ISH) with an alphoid probe was used for the detection of trisomy 8 on archival blood smears (BS). The results were compared with hybridization experiments performed on methanol/acetic acid fixed cells of cytogenetic preparations (CP) which are widely used for ISH. Fiv...

journal_title：Leukemia

authors： Bentz M,Schröder M,Herz M,Stilgenbauer S,Lichter P,Döhner H

更新日期：1993-05-01 00:00:00

abstract：:We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

journal_title：Leukemia

authors： Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

更新日期：2005-04-01 00:00:00

abstract：:Retroviral insertional mutagenesis in BXH2 mice commonly induces myeloid leukemias. One of the most frequently involved genes in experimental studies is Meis 1. In contrast to other genes in murine models, Meis 1 has not been affected by recurrent chromosomal translocations or point mutations in human leukemias. We fo...

journal_title：Leukemia

authors： Lasa A,Carnicer MJ,Aventín A,Estivill C,Brunet S,Sierra J,Nomdedéu JF

更新日期：2004-07-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is a moderately aggressive B-cell lymphoma that responds poorly to currently used therapeutic protocols. In order to identify tumour characteristics that improve the understanding of biology of MCL, analysis of oligonucleotide microarrays were used to define specific gene expression profiles...

journal_title：Leukemia

authors： Islam TC,Asplund AC,Lindvall JM,Nygren L,Liden J,Kimby E,Christensson B,Smith CI,Sander B

更新日期：2003-09-01 00:00:00

abstract：:We previously reported that susceptibility to childhood B cell precursor ALL (BCP ALL) is associated with HLA-DPB1 alleles having glutamic acid (E) rather than lysine (K) in the P4 antigenic peptide-binding pocket. Clustering approximately 90% of DPB1 alleles into DPB69E (DP2, 6, 8) and DPB69K (DP1, 3, 4) supertypes r...

journal_title：Leukemia

authors： Taylor GM,Hussain A,Verhage V,Thompson PD,Fergusson WD,Watkins G,Lightfoot T,Harrison CJ,Birch JM,UKCCS Investigators.

更新日期：2009-05-01 00:00:00

abstract：:Tumor-infiltrating T-lymphocytes (T-TIL) are putative mediators of tumor containment that exhibit unique specificity for autologous tumor cells. The magnitude of T-TIL response in biopsy specimens from patients with B-cell lymphoma has been suggested as an independent predictor of clinical outcome. Since recognition o...

journal_title：Leukemia

authors： List AF,Spier CM,Miller TP,Grogan TM

更新日期：1993-03-01 00:00:00

abstract：:The presence of rare malignant stem cells supplying a hierarchy of malignant cells has recently been reported. In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction. To understand the origin of malignant cells in primary human B-pre...

journal_title：Leukemia

authors： Kong Y,Yoshida S,Saito Y,Doi T,Nagatoshi Y,Fukata M,Saito N,Yang SM,Iwamoto C,Okamura J,Liu KY,Huang XJ,Lu DP,Shultz LD,Harada M,Ishikawa F

更新日期：2008-06-01 00:00:00

abstract：:Activating mutations in NOTCH1 are found in over 50% of human T-cell lymphoblastic leukemias (T-ALLs). Here, we report the analysis for activating NOTCH1 mutations in a large number of acute myeloid leukemia (AML) primary samples and cell lines. We found activating mutations in NOTCH1 in a single M0 primary AML sample...

journal_title：Leukemia

authors： Palomero T,McKenna K,O-Neil J,Galinsky I,Stone R,Suzukawa K,Stiakaki E,Kalmanti M,Fox EA,Caligiuri MA,Aster JC,Look AT,Ferrando AA

更新日期：2006-11-01 00:00:00

abstract：:Of 30 patients with CLL examined with gastroscopy and 18 with additional coloscopy two showed lymphocytic infiltration of the stomach as well as of the large intestine, one of the stomach, and two of the large intestine only. The lymphocytic infiltration seems to depend more on tumor burden and proliferation activity ...

journal_title：Leukemia

authors： Kuse R,Lueb H

更新日期：1997-04-01 00:00:00

abstract：:Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL tyrosine kinase domain (TKD) mutations are associated with acquired imatinib resistance, but their role in primary resistance is uncertain. Using highly sensitive ligat...

journal_title：Leukemia

authors： Pfeifer H,Lange T,Wystub S,Wassmann B,Maier J,Binckebanck A,Giagounidis A,Stelljes M,Schmalzing M,Dührsen U,Wunderle L,Serve H,Brück P,Schmidt A,Hoelzer D,Ottmann OG

更新日期：2012-07-01 00:00:00

abstract：:A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years maintenance therapy. Fifty...

journal_title：Leukemia

authors： Lengfelder E,Reichert A,Schoch C,Haase D,Haferlach T,Löffler H,Staib P,Heyll A,Seifarth W,Saussele S,Fonatsch C,Gassmann W,Ludwig WD,Hochhaus A,Beelen D,Aul C,Sauerland MC,Heinecke A,Hehlmann R,Wörmann B,Hiddemann

更新日期：2000-08-01 00:00:00

abstract：:Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detecti...

journal_title：Leukemia

authors： van der Velden VH,Cazzaniga G,Schrauder A,Hancock J,Bader P,Panzer-Grumayer ER,Flohr T,Sutton R,Cave H,Madsen HO,Cayuela JM,Trka J,Eckert C,Foroni L,Zur Stadt U,Beldjord K,Raff T,van der Schoot CE,van Dongen JJ,Euro

更新日期：2007-04-01 00:00:00

abstract：:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease that currently lacks genomic and genetic biomarkers to assist in its clinical management. We performed whole-exome sequencing (WES) of three BPDCN cases. Based on these data, we designed a resequencing approach to identify mutations in 38 sele...

journal_title：Leukemia

authors： Menezes J,Acquadro F,Wiseman M,Gómez-López G,Salgado RN,Talavera-Casañas JG,Buño I,Cervera JV,Montes-Moreno S,Hernández-Rivas JM,Ayala R,Calasanz MJ,Larrayoz MJ,Brichs LF,Gonzalez-Vicent M,Pisano DG,Piris MA,Álvarez S,

更新日期：2014-04-01 00:00:00

abstract：:Cytogenetic evolution in the myelodysplastic syndrome (MDS) has been associated with an abrupt shift to acute myelogenous leukemia (AML). To investigate the 'evolution' of MDS to AML we compared the karyotypes of MDS patients at presentation and at development of AML. Of 170 patients with MDS who developed AML, 63 had...

journal_title：Leukemia

authors： Ghaddar HM,Stass SA,Pierce S,Estey EH

更新日期：1994-10-01 00:00:00

abstract：:The human immunoglobulin lambda (Ig(lambda)) gene locus contains seven homologous C(lambda) exons which are organized in a tandem array, each of which is preceded by a single J(lambda) gene segment. The J-C(lambda)1, J-C(lambda)2, J-C(lambda)3, and J-C(lambda)7 are functional gene regions and encode for the four Ig(la...

journal_title：Leukemia

authors： Tümkaya T,Beishuizen A,Wolvers-Tettero IL,van Dongen JJ

更新日期：1996-11-01 00:00:00

abstract：:ADMIRE was a multicenter, randomized-controlled, open, phase IIB superiority trial in previously untreated chronic lymphocytic leukemia. Conventional front-line therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Initial evidence from non-randomized phase II trials suggested that the addition...

journal_title：Leukemia

authors： Munir T,Howard DR,McParland L,Pocock C,Rawstron AC,Hockaday A,Varghese A,Hamblin M,Bloor A,Pettitt A,Fegan C,Blundell J,Gribben JG,Phillips D,Hillmen P

更新日期：2017-10-01 00:00:00

abstract：:Mobilizing bone cells to the head, astutely referred to as 'bonehead' therapeutic approach, represents a major discipline of regenerative medicine. The last decade has witnessed mounting evidence supporting the capacity of bone marrow (BM)-derived cells to mobilize from BM to peripheral blood (PB), eventually finding ...

journal_title：Leukemia

authors： Borlongan CV

更新日期：2011-11-01 00:00:00

abstract：:We applied a new strategy for the detection of N-ras gene mutations based on LightCycler technology. We designed two sets of amplimers and internal hybridization probes representing N-ras codons 12/13 and codon 61, respectively. Genomic DNAs from 134 childhood acute lymphoblastic leukemia (ALL) patients (83 common ALL...

journal_title：Leukemia

authors： Nakao M,Janssen JW,Seriu T,Bartram CR

更新日期：2000-02-01 00:00:00

abstract：:As typical disorders of the elderly, myelodysplastic syndromes (MDSs) are relatively unusual in childhood. Nevertheless, up to 17% of cases of pediatric acute myeloid leukemia may have a preleukemic phase. In young patients, the goal of treatment is eradication of the preleukemic malignant clone and reconstitution of ...

journal_title：Leukemia

authors： Locatelli F,Pession A,Bonetti F,Maserati E,Prete L,Pedrazzoli P,Zecca M,Prete A,Paolucci P,Cazzola M

更新日期：1994-05-01 00:00:00

abstract：:The role of endothelial progenitor cell (EPC)-mediated vasculogenesis in hematological malignancies is not well explored. Here, we showed that EPCs are mobilized from the bone marrow (BM) to the peripheral blood at early stages of multiple myeloma (MM); and recruited to MM cell-colonized BM niches. Using EPC-defective...

journal_title：Leukemia

authors： Moschetta M,Mishima Y,Kawano Y,Manier S,Paiva B,Palomera L,Aljawai Y,Calcinotto A,Unitt C,Sahin I,Sacco A,Glavey S,Shi J,Reagan MR,Prosper F,Bellone M,Chesi M,Bergsagel LP,Vacca A,Roccaro AM,Ghobrial IM

更新日期：2016-05-01 00:00:00

abstract：:Children with Down's syndrome (DS) have an increased risk of developing acute lymphoblastic leukemia (ALL) and have a low frequency of established genetic aberrations. We aimed to determine which genetic abnormalities are involved in DS ALL. We studied the frequency and prognostic value of deletions in B-cell developm...

journal_title：Leukemia

authors： Buitenkamp TD,Pieters R,Gallimore NE,van der Veer A,Meijerink JP,Beverloo HB,Zimmermann M,de Haas V,Richards SM,Vora AJ,Mitchell CD,Russell LJ,Schwab C,Harrison CJ,Moorman AV,van den Heuvel-Eibrink MM,den Boer ML,Zwaan

更新日期：2012-10-01 00:00:00